<Header>
<FileStats>
    <FileName>20240327_10-K-A_edgar_data_1417926_0001493152-24-011557.txt</FileName>
    <GrossFileSize>294234</GrossFileSize>
    <NetFileSize>8564</NetFileSize>
    <NonText_DocumentType_Chars>74537</NonText_DocumentType_Chars>
    <HTML_Chars>78931</HTML_Chars>
    <XBRL_Chars>69508</XBRL_Chars>
    <XML_Chars>56466</XML_Chars>
    <N_Exhibits>6</N_Exhibits>
</FileStats>
<SEC-Header>
0001493152-24-011557.hdr.sgml : 20240327
<ACCEPTANCE-DATETIME>20240327172408
ACCESSION NUMBER:		0001493152-24-011557
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20240327
DATE AS OF CHANGE:		20240327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INVO Bioscience, Inc.
		CENTRAL INDEX KEY:			0001417926
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				204036208
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39701
		FILM NUMBER:		24792080

	BUSINESS ADDRESS:	
		STREET 1:		5582 BROADCAST COURT
		CITY:			SARASOTA
		STATE:			FL
		ZIP:			34240
		BUSINESS PHONE:		(978) 878-9505

	MAIL ADDRESS:	
		STREET 1:		5582 BROADCAST COURT
		CITY:			SARASOTA
		STATE:			FL
		ZIP:			34240

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMY'S SALSA AJI DISTRIBUTION COMPANY, INC.
		DATE OF NAME CHANGE:	20071108

</SEC-Header>
</Header>

 0001493152-24-011557.txt : 20240327

10-K/A
 1
 form10-ka.htm

UNITED
STATES 

 SECURITIES
AND EXCHANGE COMMISSION 

 WASHINGTON,
D.C. 20549 

FORM

(Amendment
No. 2) 

Annual
 Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

For
 the fiscal year ended , 

or 

Transition
 Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

For
 the transition period from to 

(Exact
name of registrant as specified in Charter) 

(State
 or other jurisdiction of 
 incorporation or organization) 
 
 (Commission 
 File
 No.) 
 
 (IRS
 Employee 
 Identification
 No.) 

, , 

 (Address
of Principal Executive Offices) 

Registrant s
telephone number, including area code: 

Securities
registered pursuant to Section 12(b) of the Act: 

Title
 of each class 
 
 Trading
 symbol(s) 
 
 Name
 of each exchange on which registered 

Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES NO 

Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES NO 

Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. YES NO 

Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). YES NO 

Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, 
 smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act. 

Large
 accelerated filer 
 Accelerated
 filer 

Smaller
 reporting company 

Emerging
 growth company 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate
by check mark whether the registrant has filed a report on and attestation to its management s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. Yes No 

If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. Yes No 

Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant s executive officers during the relevant recovery period pursuant to 240.10D-1(b). 

Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES NO 

The
aggregate market value of the voting stock and non-voting common equity held by non-affiliates of the registrant as of the last business
day of the registrant s most recently completed second fiscal quarter ended June 30, 2022 was based upon the closing
price of the registrant s common stock of 0.64 on the NASDAQ as of that date. 

The
number of shares outstanding of the registrant s common stock, 0.0001 par value, as of April 17, 2023 was . 

DOCUMENTS
INCORPORATED BY REFERENCE 

. 

Audit
 Firm Id 
 
 Auditor
 Name: 
 
 Auditor
 Location: 

Explanatory
Note 

In
addition, Item 15 of Part IV is being amended solely to include currently dated certifications in accordance with Rule 12b-15 promulgated
by the SEC under the Securities Exchange Act of 1934, as amended, with paragraphs 3, 4, and 5 omitted, since no financial statements
are contained within this Amendment. Because no financial statements are contained within this Amendment, the Company is not including
certifications pursuant to Section 906 of the Sarbanes-Oxley Act 0f 2002 or any disclosures with respect to Items 307 or 308 of Regulation
S-K. 

Except
as described above, no other changes have been made to the Original Filing or the First Amendment. The Original Filing and the First
Amendment continue to speak as of the date of the Original Filing and the First Amendment, respectively, and we have not updated the
disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing or the First
Amendment, respectively. Accordingly, this Amendment should be read in conjunction with our Original Filing, the First Amendment, and
our other filings made with the SEC subsequent to the filing of the Form 10-K. 

Part
IV 

Item
15. Exhibits and Financial Statement Schedules 

(a) 
 The
 following documents are filed as part of this report: 

3.
Exhibits: 

The
exhibits listed in the Original Filing and the exhibits listed below in this Amendment are filed with, or incorporated by reference in,
this report. 

Exhibit
 No. 
 
 Description 

23.1 
 
 Consent of M K CPAs, PLLC. 
 
 31.5 
 
 Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended. 
 
 31.6 
 
 Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities ended. Exchange Act of 1934, as amended. 

Item
16. Form 10-K Summary 

Not
applicable. 

SIGNATURES 

Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report
on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized on March 27, 2024. 

INVO
 Bioscience, Inc. 

Date:
 March 27, 2024 
 By: 
 /s/
 Steven Shum 

Steven
 Shum 

Chief
 Executive Officer 
 (Principal
 Executive Officer) 

<EX-23.1>
 2
 ex23-1.htm

Exhibit
23.1 

CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

We
hereby consent to the incorporation in Registration Statements on Forms S-3 and S-8 Nos. 333-234230, 333-252228, 333-255096, 333-263239,
and 333-269258 of our report dated April 17, 2023, of INVO Bioscience, Inc. relating to the audit of the consolidated financial statements
as of December 31, 2022 and 2021, and for the periods then ended, including an explanatory paragraph regarding the Company s ability
to continue as a going concern, and the reference to our firm under the caption Experts in the Registration Statement. 

/s/
 M K CPA s, PLLC 

Houston,
 TX 

March
 27, 2024 

</EX-23.1>

<EX-31.5>
 3
 ex31-5.htm

EXHIBIT
31.5 

CERTIFICATION
BY THE PRINCIPAL EXECUTIVE OFFICER 

 PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 

I,
Steven Shum, certify that: 

1.
I have reviewed this Annual Report on Form 10-K/A of INVO Bioscience, Inc.; 

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report; 

Date:
 March 27, 2024 
 /s/
 Steven Shum 

Steven
 Shum 
 Chief
 Executive Officer 

</EX-31.5>

<EX-31.6>
 4
 ex31-6.htm

EXHIBIT
31.6 

CERTIFICATION
BY THE PRINCIPAL FINANCIAL OFFICER 

 PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 

I,
Andrea Goren, certify that: 

1.
I have reviewed this Annual Report on Form 10-K/A of INVO Bioscience, Inc.; 

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report; 

Date:
 March 27, 2024 
 /s/
 Andrea Goren 

Andrea
 Goren 
 Chief
 Financial Officer 

</EX-31.6>

<EX-101.SCH>
 5
 invo-20221231.xsd
 XBRL SCHEMA FILE

</EX-101.LAB>

<EX-101.PRE>
 7
 invo-20221231_pre.xml
 XBRL PRESENTATION FILE

</EX-101.PRE>

